Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-week Open-label, Randomised, Parallel-group, Multicentre, Phase IIIb Study to Compare the Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe and Simvastatin in Patients With Hypercholesterolaemia and CHD

NCT00525824 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00525824
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00525824 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-week Open-label, Randomised, Parallel-group, Multicentre, Phase IIIb Study to Compare the Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe and Simvastatin in Patients With Hypercholesterolaemia and CHD
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2007
Completion date
September 30, 2008
Enrollment
1,743 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerosis, coronary heart disease, hypercholesterolemia